Folic Acid vs 5-MTHF for Prenatal Supplementation
Women planning pregnancy should take 400-800 μg of folic acid daily, as this is the only form with established Grade A evidence for neural tube defect prevention. While 5-MTHF is an acceptable alternative that maintains adequate folate status and reduces unmetabolized folic acid, the landmark trials proving NTD prevention used folic acid, not 5-MTHF 1.
The Evidence-Based Recommendation
The USPSTF provides Grade A evidence (highest level) recommending 0.4 to 0.8 mg (400-800 μg) of folic acid daily for all women planning or capable of pregnancy 1. This should begin at least 1 month before conception and continue through the first trimester. Given that 50% of pregnancies are unplanned, all women of reproductive age should supplement.
Why Folic Acid Remains the Gold Standard
- Proven efficacy: The original RCTs demonstrating 50-67% reduction in neural tube defects used folic acid, not 5-MTHF 1
- Established safety profile: Decades of use with no serious harms at recommended doses 1
- Universal availability: Standard in prenatal vitamins and fortified foods
The Case for 5-MTHF as an Alternative
Recent research shows 5-MTHF may offer specific advantages:
Equivalent folate status: Studies demonstrate that 5-MTHF (416-625 μg) maintains maternal and fetal folate concentrations comparable to folic acid 2, 3, 4. One trial showed 5-MTHF actually increased red blood cell folate more than folic acid over 24 weeks 4.
Reduced unmetabolized folic acid (UMFA): This is the key differentiator. Women taking 5-MTHF have:
- 50% lower plasma UMFA concentrations 3
- 7% vs 31% with detectable UMFA in maternal blood 2
- Lower placental UMFA accumulation 2
Bypasses metabolic bottleneck: 5-MTHF doesn't require hepatic conversion by dihydrofolate reductase, which has limited capacity 5, 6. This matters for women with:
- MTHFR C677T polymorphism (reduced enzyme activity)
- Medications interfering with folate metabolism (methotrexate, anticonvulsants) 7
- Liver dysfunction
Clinical Decision Algorithm
Use standard folic acid (400-800 μg) for:
- All women as first-line recommendation
- Women without access to 5-MTHF products
- Women with undiagnosed anemia (folic acid won't mask B12 deficiency as readily) 7
Consider 5-MTHF (400-600 μg) for:
- Women with known MTHFR polymorphisms
- Those taking anticonvulsants (phenytoin, carbamazepine, valproic acid) 1, 7
- Women concerned about UMFA accumulation
- Those with documented difficulty metabolizing folic acid
Use higher doses (4-5 mg folic acid) for:
- Previous pregnancy with neural tube defect
- Women taking antiseizure medications 1
Critical Caveats
The UMFA concern remains theoretical: While 5-MTHF reduces circulating UMFA, the biological significance and clinical impact on pregnancy outcomes are unknown 2, 3, 6. No studies demonstrate that UMFA causes harm at supplementation doses.
Timing is crucial: Supplementation must begin before conception. Neural tube closure occurs by day 28 post-conception, often before pregnancy recognition 1. The 4-week preconception window may be insufficient—studies suggest 12+ weeks for maximal red blood cell folate accumulation 4.
Avoid excessive doses: Folic acid >0.4 mg daily can mask pernicious anemia (B12 deficiency), allowing neurologic damage to progress while correcting hematologic abnormalities 7. This risk applies to both forms.
Drug interactions: Folic acid antagonizes phenytoin's anticonvulsant effects—patients may require dose adjustments 7. Methotrexate, trimethoprim, and other folate antagonists increase folate requirements.
Practical Implementation
The most pragmatic approach: Recommend 400-800 μg folic acid as standard, with 5-MTHF as an acceptable alternative for women with specific indications or strong preference. Both forms achieve the primary goal of preventing neural tube defects when taken appropriately.
The evidence shows 5-MTHF is non-inferior for maintaining folate status 2, 3, 4 and superior for reducing UMFA 2, 3, but folic acid has the proven track record for the outcome that matters most: preventing devastating birth defects with 50-67% efficacy 1.